Ibrutinib

Ibrutinib Reactions 1680, p163 - 2 Dec 2017 Various toxicities: 2 case reports In a case series, two patients were described, out of whom a 79-year-old woman developed nail plate abnormalities, ecchymoses and actinic keratosis, and a 53-year-old man developed nail plate abnormalities, desquamative dermatitis with red-brown macules and petechiae during treatment with ibrutinib [not all outcomes stated]. Case 1: A 79-year-old woman, who had a history of chronic lymphocytic leukaemia (CLL), was started on systemic treatment with oral ibrutinib 420mg daily. Within six months from the start of ibrutinib, she observed changes in the texture and appearance of her nails. Cutaneous skin examination showed significant changes of her fingernails and toenails with brittle and fragile nature. Therefore, she was started on biotin. In addition to the nail changes, she also developed ecchymoses on her arms and legs. She had ten actinic keratosis, which was treated with cryotherapy. Three months after the start of biotin, her toenails brittleness improved. However, new ecchymoses continued to grow on her extremities. Case 2: A 53-year-old man, who had a history of CLL, was started on systemic treatment with oral ibrutinib 420mg daily. He also received venetoclax (ABT199). Within four months from the start of ibrutinib, he observed changes in the appearance of his nails. Cutaneous skin examination showed significant changes of the nails on finger, thumb and toe with brittle and fragile nature. Therefore, he was started on biotin. In addition to the nail changes, he also developed ecchymoses desquamative dermatitis with red-brown macules. He also had petechiae on the tip of the left great toe. Author comment: "Ibrutinib, a tyrosine kinase inhibitor, is a novel therapy for chronic lymphocytic leukemia that has been associated with nail plate abnormalities." "Bruising, hair changes and nail plate abnormalities, pruritus and rashes are the most common cutaneous side effects of ibrutinib; less common skin adverse events include purpuric painful nodules and pyoderma gangrenosum." Heldt Manica LA, et al. Ibrutinib-Associated Nail Plate Abnormalities: Case Reports and Review. Drug Safety - Case Reports 4: No. 15, Dec 2017. Available from: URL: http://doi.org/10.1007/s40800-017-0060-1 - USA 803284587 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Reactions Weekly Springer Journals

Ibrutinib

Reactions Weekly , Volume 1680 (1) – Dec 2, 2017
Free
1 page
Loading next page...
1 Page
 
/lp/springer_journal/ibrutinib-ODq7tEr002
Publisher
Springer International Publishing
Copyright
Copyright © 2017 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
ISSN
0114-9954
eISSN
1179-2051
D.O.I.
10.1007/s40278-017-39094-2
Publisher site
See Article on Publisher Site

Abstract

Reactions 1680, p163 - 2 Dec 2017 Various toxicities: 2 case reports In a case series, two patients were described, out of whom a 79-year-old woman developed nail plate abnormalities, ecchymoses and actinic keratosis, and a 53-year-old man developed nail plate abnormalities, desquamative dermatitis with red-brown macules and petechiae during treatment with ibrutinib [not all outcomes stated]. Case 1: A 79-year-old woman, who had a history of chronic lymphocytic leukaemia (CLL), was started on systemic treatment with oral ibrutinib 420mg daily. Within six months from the start of ibrutinib, she observed changes in the texture and appearance of her nails. Cutaneous skin examination showed significant changes of her fingernails and toenails with brittle and fragile nature. Therefore, she was started on biotin. In addition to the nail changes, she also developed ecchymoses on her arms and legs. She had ten actinic keratosis, which was treated with cryotherapy. Three months after the start of biotin, her toenails brittleness improved. However, new ecchymoses continued to grow on her extremities. Case 2: A 53-year-old man, who had a history of CLL, was started on systemic treatment with oral ibrutinib 420mg daily. He also received venetoclax (ABT199). Within four months from the start of ibrutinib, he observed changes in the appearance of his nails. Cutaneous skin examination showed significant changes of the nails on finger, thumb and toe with brittle and fragile nature. Therefore, he was started on biotin. In addition to the nail changes, he also developed ecchymoses desquamative dermatitis with red-brown macules. He also had petechiae on the tip of the left great toe. Author comment: "Ibrutinib, a tyrosine kinase inhibitor, is a novel therapy for chronic lymphocytic leukemia that has been associated with nail plate abnormalities." "Bruising, hair changes and nail plate abnormalities, pruritus and rashes are the most common cutaneous side effects of ibrutinib; less common skin adverse events include purpuric painful nodules and pyoderma gangrenosum." Heldt Manica LA, et al. Ibrutinib-Associated Nail Plate Abnormalities: Case Reports and Review. Drug Safety - Case Reports 4: No. 15, Dec 2017. Available from: URL: http://doi.org/10.1007/s40800-017-0060-1 - USA 803284587 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680

Journal

Reactions WeeklySpringer Journals

Published: Dec 2, 2017

There are no references for this article.

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off